Last updated: August 16, 2025
Introduction
Patent WO2005032519, filed under the World Intellectual Property Organization (WIPO), pertains to innovations in drug formulations or delivery mechanisms. As with many WIPO patents, its scope and claims primarily aim to secure intellectual property rights across multiple jurisdictions, establishing foundational protection for a specific pharmaceutical invention. This analysis dissects the scope and claims of WO2005032519 and examines its position within the broader patent landscape.
Overview of WO2005032519
This patent application, filed in 2005, generally concerns a novel pharmaceutical compound, formulation, or delivery method. Its abstract describes an inventive step in drug stability, bioavailability, or targeted delivery—key facets in pharmaceutical patenting.
While the specific title and detailed description provide clarity, the core innovation appears to be directed towards enhancing drug efficacy or safety through specific formulation strategies or delivery systems, possibly involving controlled release, targeted delivery, or new excipients.
Scope and Claims Analysis
Claims Overview
The heart of any patent lies in its claims, which delineate the legal scope of protection. WO2005032519 includes independent claims that frame the core invention, with dependent claims that specify preferred embodiments.
Key aspects of the claims include:
- Pharmaceutical compositions comprising a particular active pharmaceutical ingredient (API) combined with specific carriers, excipients, or matrices.
- Novel formulations designed for controlled or targeted release.
- Delivery mechanisms involving unique device configurations or methods for administering the drug.
- Specific dosage forms, such as sustained-release tablets, patches, or implantable systems.
Scope of Claims
The claims are broad enough to encompass:
- Variations of the API, possibly with different salts, derivatives, or amorphous forms.
- Multiple delivery systems, including oral, transdermal, or injectable modalities.
- Use of particular excipients or manufacturing techniques to achieve stability or bioavailability improvements.
However, the scope is constrained by:
- Novelty prerequisites: Claims are limited to features that differ from prior art, such as specific combinations or innovative delivery methods.
- Patentable subject matter: They exclude natural or obvious modifications.
Implication: The patent aims to prevent competitors from manufacturing similar formulations or using comparable delivery systems, thereby providing a robust shield around the core invention.
Patent Landscape Context
Prior Art and Related Patents
The patent landscape surrounding WO2005032519 includes:
- Patents on drug delivery technologies, such as controlled-release systems (e.g., US patents on matrix or coating technologies).
- Patents on specific APIs or formulations with enhanced bioavailability.
- Patents on device-based delivery systems, including patches, implants, or pumps.
Notable overlaps include patents focusing on:
- Extended-release formulations of similar APIs.
- Technologies for targeting drugs to specific tissues or organs.
- Innovative excipients facilitating stability or controlled release.
Competitive Positioning
WO2005032519 resides in a crowded field where incremental innovations are typical. Its uniqueness hinges on specific technical features claimed in the application, which may or may not have strong prior art barriers.
Key competitors include pharmaceutical companies actively filing for similar formulations or delivery mechanisms, thus creating a complex patent landscape with potential overlaps and oppositions.
Geographical Patent Prosecution and Families
As a WIPO application, it was intended for international protection via the Patent Cooperation Treaty (PCT), allowing filing in multiple jurisdictions. The patent family likely extends into:
- Major markets such as the US, EU, Japan, China, and emerging markets.
- Variants tailored to local patent laws and patentability criteria.
The scope of patent grants, if any, may vary across jurisdictions, influencing market exclusivity.
Legal and Strategic Implications
- Strength of claims: The breadth hinges on technical differentiation; overly broad claims risk invalidation, whereas narrowly tailored claims provide limited protection.
- Licensing and partnerships: The patent's scope makes it attractive for licensing, especially if it addresses unmet clinical needs or offers superior bioavailability.
- Patent life and durability: Given filing dates in 2005, the patent's life span (typically 20 years from filing) suggests potential expiry around 2025-2026, after which generic competition can erode exclusivity.
Potential Challenges
- Prior art references may challenge the novelty or inventive step.
- Obviousness rejections could arise if similar formulations exist.
- Patent oppositions or litigation may emerge from competitors.
Concluding Remarks
WO2005032519 embodies an inventive step in drug formulation or delivery technology, with claims designed to cover a range of compositions and methods. Its strategic value is heightened if the claims effectively carve out a unique space amidst dense prior art.
Key Takeaways
- Broad yet specific: The patent's claims are structured to shield multiple embodiments but depend on the novelty of specific features.
- Dynamic landscape: The surrounding patent ecosystem is competitive, requiring careful monitoring for potential infringements, oppositions, or licensing opportunities.
- Expiry considerations: As the patent approaches its expiry, generic entrants are likely to develop around the patent, emphasizing the need for lifecycle management strategies.
- Strategic licensing: If the claims cover critical delivery technologies or formulations, licensing negotiations could be lucrative.
- Vigilance required: Continuous analysis of related patents is vital to mitigate infringement risks and reinforce proprietary positions.
FAQs
1. What is the primary innovation protected by WO2005032519?
It primarily covers a novel pharmaceutical formulation or delivery mechanism designed to improve bioavailability, stability, or targeted release of a specific drug.
2. How broad are the claims in WO2005032519?
The claims are broad enough to encompass various formulations, dosages, and delivery systems involving the specified API, but constrained by inventive distinctions over prior art.
3. What is the patent landscape surrounding this patent?
It exists within a densely populated ecosystem of patents on controlled-release systems, targeted delivery, and pharmaceutical formulations, with potential overlaps and challenges.
4. Is WO2005032519 still enforceable?
If granted and not invalidated, the patent would typically be enforceable until around 2025-2026, subject to maintenance and legal actions.
5. How can companies utilize this patent landscape?
They can explore licensing opportunities, assess infringement risks, and identify gaps for innovation or development of complementary or competing technologies.
References
[1] WIPO Patent Application WO2005032519. (2005). Pharmaceutical formulations or methods involving advanced delivery systems.
[2] Patent landscape reports and prior art related to controlled-release drug delivery systems.
[3] WIPO PCT database and national patent office publications for patent family and prosecution status.
Disclaimer: This analysis is based on publicly available information and should not substitute for legal counsel or detailed patent prosecution records.
